RU2013114980A - Вакцинная композиция - Google Patents
Вакцинная композиция Download PDFInfo
- Publication number
- RU2013114980A RU2013114980A RU2013114980/15A RU2013114980A RU2013114980A RU 2013114980 A RU2013114980 A RU 2013114980A RU 2013114980/15 A RU2013114980/15 A RU 2013114980/15A RU 2013114980 A RU2013114980 A RU 2013114980A RU 2013114980 A RU2013114980 A RU 2013114980A
- Authority
- RU
- Russia
- Prior art keywords
- vaccine composition
- salt
- composition according
- isolated
- antigen
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 25
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 239000000427 antigen Substances 0.000 claims abstract 13
- 102000036639 antigens Human genes 0.000 claims abstract 13
- 108091007433 antigens Proteins 0.000 claims abstract 13
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims abstract 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims abstract 6
- 150000002632 lipids Chemical class 0.000 claims abstract 6
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 6
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims abstract 5
- 239000002158 endotoxin Substances 0.000 claims abstract 5
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract 5
- 239000003970 toll like receptor agonist Substances 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 4
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims abstract 4
- 108010028921 Lipopeptides Proteins 0.000 claims abstract 4
- 241000607142 Salmonella Species 0.000 claims abstract 4
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 208000015181 infectious disease Diseases 0.000 claims abstract 4
- 241000520272 Pantoea Species 0.000 claims abstract 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract 3
- DMWMUMWKGKGSNW-OPMCLZTFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-[(2R)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC DMWMUMWKGKGSNW-OPMCLZTFSA-N 0.000 claims abstract 2
- 241001468161 Acetobacterium Species 0.000 claims abstract 2
- 241000588914 Enterobacter Species 0.000 claims abstract 2
- 241000588724 Escherichia coli Species 0.000 claims abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract 2
- 101710176177 Protein A56 Proteins 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims abstract 2
- 241000589634 Xanthomonas Species 0.000 claims abstract 2
- 241000588901 Zymomonas Species 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 claims abstract 2
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 claims abstract 2
- -1 glucopyranosyl lipid Chemical class 0.000 claims abstract 2
- 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 claims abstract 2
- 210000000214 mouth Anatomy 0.000 claims abstract 2
- 230000028993 immune response Effects 0.000 claims 4
- 210000004877 mucosa Anatomy 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 229940123560 Toll-like receptor 4 agonist Drugs 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Вакцинная композиция для введения в ротовую полость человека или животного, причем вакцинная композиция включает:по меньшей мере один антиген, выделенный из объекта с инфекционным заболеванием, ипо меньшей мере один агент, выбранный из группы, состоящей из:агониста toll-подобного рецептора 4 (TLR4),агониста toll-подобного рецептора 2/6 (TLR2/6) ициклического динуклеотида или их производного или соли.2. Вакцинная композиция по п.1, где антиген, выделенный из объекта с инфекционным заболеванием, представляет собой антиген, выделенный из вируса гриппа.3. Вакцинная композиция по п.2, где антиген, выделенный из вируса гриппа, представляет собой белок гемагглютинин.4. Вакцинная композиция по п.2, где антиген, выделенный из вируса гриппа, представляет собой инактивированный цельный вирус.5. Вакцинная композиция по п.1, где агонист toll-подобного рецептора 4 (TLR4) включает по меньшей мере один агент, выбранный из группы, состоящей из:липополисахарида или его соли имонофосфориллипида или его соли.6. Вакцинная композиция по п.5, где липополисахарид или его соль выделены из Escherichia coli, Salmonella, Pantoea, Acetobacterium, Zymomonas, Xanthomonas или Enterobacter; имонофосфориллипид или его соль представляет собой монофосфориллипид, выделенный из Salmonella, или синтетический глюкопиранозиллипид.7. Вакцинная композиция по п.1, где агонист toll-подобного рецептора 2/6 (TLR2/6) включает диацилированный липопептид или его производное или соль.8. Вакцинная композиция по п.7, где диацилированный липопептид включает PamCSK, MALP-2, FSL-1 или их производные или соли.9. Вакцинная композиция по п.1, где циклический динуклеотид включает c-di-GMP, c-di-AMP или их производные или соли.10. Вакцинная композиция по п.6, где ли
Claims (11)
1. Вакцинная композиция для введения в ротовую полость человека или животного, причем вакцинная композиция включает:
по меньшей мере один антиген, выделенный из объекта с инфекционным заболеванием, и
по меньшей мере один агент, выбранный из группы, состоящей из:
агониста toll-подобного рецептора 4 (TLR4),
агониста toll-подобного рецептора 2/6 (TLR2/6) и
циклического динуклеотида или их производного или соли.
2. Вакцинная композиция по п.1, где антиген, выделенный из объекта с инфекционным заболеванием, представляет собой антиген, выделенный из вируса гриппа.
3. Вакцинная композиция по п.2, где антиген, выделенный из вируса гриппа, представляет собой белок гемагглютинин.
4. Вакцинная композиция по п.2, где антиген, выделенный из вируса гриппа, представляет собой инактивированный цельный вирус.
5. Вакцинная композиция по п.1, где агонист toll-подобного рецептора 4 (TLR4) включает по меньшей мере один агент, выбранный из группы, состоящей из:
липополисахарида или его соли и
монофосфориллипида или его соли.
6. Вакцинная композиция по п.5, где липополисахарид или его соль выделены из Escherichia coli, Salmonella, Pantoea, Acetobacterium, Zymomonas, Xanthomonas или Enterobacter; и
монофосфориллипид или его соль представляет собой монофосфориллипид, выделенный из Salmonella, или синтетический глюкопиранозиллипид.
7. Вакцинная композиция по п.1, где агонист toll-подобного рецептора 2/6 (TLR2/6) включает диацилированный липопептид или его производное или соль.
8. Вакцинная композиция по п.7, где диацилированный липопептид включает Pam2CSK4, MALP-2, FSL-1 или их производные или соли.
9. Вакцинная композиция по п.1, где циклический динуклеотид включает c-di-GMP, c-di-AMP или их производные или соли.
10. Вакцинная композиция по п.6, где липополисахарид или его соль выделены из Pantoea.
11. Вакцинная композиция по п.1, где вакцинная композиция индуцирует иммунный ответ слизистой и системный иммунный ответ, причем иммунный ответ слизистой представляет собой выработку антиген-специфичного антитела IgA, а системный иммунный ответ представляет собой выработку антиген-специфичного антитела IgG, а также развитие антиген-специфичного клеточно-опосредованного иммунитета.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012085839 | 2012-04-04 | ||
| JP2012-085839 | 2012-04-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013114980A true RU2013114980A (ru) | 2014-10-10 |
| RU2655627C2 RU2655627C2 (ru) | 2018-05-29 |
Family
ID=48044517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013114980A RU2655627C2 (ru) | 2012-04-04 | 2013-04-03 | Вакцинная композиция |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9498527B2 (ru) |
| EP (3) | EP3485904A1 (ru) |
| JP (3) | JP5650780B2 (ru) |
| KR (1) | KR102103606B1 (ru) |
| CN (2) | CN107961374B (ru) |
| CA (1) | CA2811762C (ru) |
| ES (1) | ES2568018T3 (ru) |
| PL (1) | PL2647387T3 (ru) |
| RU (1) | RU2655627C2 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5650780B2 (ja) * | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | ワクチン組成物 |
| KR102255996B1 (ko) | 2012-12-19 | 2021-05-26 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화 |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| HK1219054A1 (zh) * | 2013-10-03 | 2017-03-24 | 日东电工株式会社 | 粘膜疫苗组合物 |
| WO2015050178A1 (ja) * | 2013-10-03 | 2015-04-09 | 日東電工株式会社 | 鼻粘膜ワクチン組成物 |
| JP6494233B2 (ja) * | 2013-10-03 | 2019-04-03 | 日東電工株式会社 | 粘膜ワクチン組成物 |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| TW201618790A (zh) * | 2014-10-02 | 2016-06-01 | Nitto Denko Corp | 經皮投與用疫苗醫藥組合物 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016130616A1 (en) | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
| BR112017022585A2 (pt) * | 2015-05-01 | 2018-07-17 | Nitto Denko Corporation | composição de vacina de alergia |
| RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JP6977206B2 (ja) * | 2016-03-31 | 2021-12-08 | 富山県 | 自然免疫を活性化する粘膜ワクチン用アジュバント |
| BR112022018160A2 (pt) * | 2020-03-24 | 2022-10-25 | Byung Chul Ahn | Método de produção de composição de soro para prevenir ou tratar doenças infecciosas relacionadas à mucosa em mamíferos jovens, composição de soro produzida por ele, e uso da mesma |
| WO2025157994A1 (en) * | 2024-01-25 | 2025-07-31 | Intervet International B.V. | Vaccine against ruminant respiratory disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120310A (zh) * | 1993-03-11 | 1996-04-10 | 塞科雷泰克公司 | 在粘膜表面转运免疫原的聚合粘膜粘合剂 |
| JP4043533B2 (ja) * | 1995-01-27 | 2008-02-06 | 水野 傳一 | 低分子量リポポリサッカライド |
| JPH08245702A (ja) * | 1995-03-13 | 1996-09-24 | Denichi Mizuno | 高分子量リポポリサッカライド |
| GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| US20050276813A1 (en) | 2002-04-04 | 2005-12-15 | Peter Muhlradt | Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations |
| CA2560058C (en) | 2004-03-15 | 2011-10-18 | David K.R. Karaolis | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| EP1782826A1 (en) * | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| WO2007061102A1 (ja) * | 2005-11-28 | 2007-05-31 | Biomedical Research Group Inc. | 発酵及び培養方法、植物発酵エキス、植物発酵エキス配合物、リポ多糖製造方法並びにリポ多糖 |
| US20080044438A1 (en) | 2006-03-17 | 2008-02-21 | Ostroff Gary R | Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
| US20080112974A1 (en) | 2006-09-08 | 2008-05-15 | Duotol Ab | Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens |
| US20100150952A1 (en) * | 2008-11-07 | 2010-06-17 | University Of Washington | pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| US9849173B2 (en) * | 2009-07-06 | 2017-12-26 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| US20120058154A1 (en) * | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e |
| JP5650780B2 (ja) * | 2012-04-04 | 2015-01-07 | 日東電工株式会社 | ワクチン組成物 |
-
2013
- 2013-03-29 JP JP2013073406A patent/JP5650780B2/ja not_active Expired - Fee Related
- 2013-04-03 RU RU2013114980A patent/RU2655627C2/ru active
- 2013-04-03 EP EP18210088.3A patent/EP3485904A1/en not_active Withdrawn
- 2013-04-03 ES ES13001690.0T patent/ES2568018T3/es active Active
- 2013-04-03 EP EP13001690.0A patent/EP2647387B1/en not_active Not-in-force
- 2013-04-03 EP EP16000035.2A patent/EP3031468A1/en not_active Withdrawn
- 2013-04-03 US US13/856,002 patent/US9498527B2/en not_active Expired - Fee Related
- 2013-04-03 PL PL13001690.0T patent/PL2647387T3/pl unknown
- 2013-04-03 KR KR1020130036293A patent/KR102103606B1/ko not_active Expired - Fee Related
- 2013-04-04 CA CA2811762A patent/CA2811762C/en active Active
- 2013-04-07 CN CN201711366441.3A patent/CN107961374B/zh not_active Expired - Fee Related
- 2013-04-07 CN CN2013101179550A patent/CN103357010A/zh active Pending
-
2014
- 2014-11-13 JP JP2014230744A patent/JP2015028092A/ja active Pending
-
2016
- 2016-10-11 US US15/290,031 patent/US20170028054A1/en not_active Abandoned
-
2017
- 2017-02-24 JP JP2017033269A patent/JP6378380B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-18 US US16/996,433 patent/US20200376111A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2647387T3 (pl) | 2016-09-30 |
| EP3031468A1 (en) | 2016-06-15 |
| JP2017114898A (ja) | 2017-06-29 |
| CA2811762A1 (en) | 2013-10-04 |
| US20170028054A1 (en) | 2017-02-02 |
| KR20130112790A (ko) | 2013-10-14 |
| EP3485904A1 (en) | 2019-05-22 |
| CN107961374B (zh) | 2021-10-01 |
| EP2647387A1 (en) | 2013-10-09 |
| US9498527B2 (en) | 2016-11-22 |
| US20130266612A1 (en) | 2013-10-10 |
| EP2647387B1 (en) | 2016-03-30 |
| CN107961374A (zh) | 2018-04-27 |
| CA2811762C (en) | 2021-09-14 |
| KR102103606B1 (ko) | 2020-04-22 |
| JP2015028092A (ja) | 2015-02-12 |
| JP5650780B2 (ja) | 2015-01-07 |
| RU2655627C2 (ru) | 2018-05-29 |
| US20200376111A1 (en) | 2020-12-03 |
| ES2568018T3 (es) | 2016-04-27 |
| CN103357010A (zh) | 2013-10-23 |
| JP2013231026A (ja) | 2013-11-14 |
| JP6378380B2 (ja) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013114980A (ru) | Вакцинная композиция | |
| Honda-Okubo et al. | Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses | |
| Riese et al. | Vaccine adjuvants: key tools for innovative vaccine design | |
| Ghendon et al. | Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines | |
| EA200701786A1 (ru) | Поливалентная противогриппозная иммуногенная композиция | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| EP4056198A3 (en) | Outer membrane vesicles | |
| EA200900024A1 (ru) | Противогриппозная вакцина | |
| AR059647A1 (es) | Antigenos vacunales quimericos contra el virus de la influenza aviar | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| Shim et al. | Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets | |
| CA2951982C (en) | Rhinovaccination system of influenza vaccine | |
| Cargnelutti et al. | Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant | |
| JP6494232B2 (ja) | 粘膜ワクチン組成物 | |
| US20110189231A1 (en) | Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines | |
| Kang et al. | A novel combined adjuvant strongly enhances mucosal and systemic immunity to low pathogenic avian influenza after oral immunization in ducks | |
| RU2009114430A (ru) | Способ вакцинации птицы против гриппа и болезни ньюкасла | |
| MX2014014089A (es) | Peptido recombinante de la porina de 42-kda, uso como antigeno vacunal y en la deteccion de anticuerpos contra histophilus somni. | |
| Nie Jie et al. | Comparison of serum and egg yolk antibodies induced by different doses of CpG-ODN adjuvant combined with ALV-J gp85 recombinant proteins in breeding hens (Gallus domesticus). | |
| UA60016U (ru) | Способ повышения иммунного ответа при вакцинации птицы | |
| UA40193U (ru) | Способ in ovo вакцинации против инфекционных болезней птицы | |
| CY1115921T1 (el) | Εμβολιο γριπης | |
| AR088365A1 (es) | Adjuvantes para vacunas polisacaridicas y las formulaciones resultantes | |
| SG160386A1 (en) | Novel composition |